CLARK IAN T 4
4 · Corvus Pharmaceuticals, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Corvus (CRVS) Director Ian T. Clark Receives Award of 15,000 Options
What Happened
Ian T. Clark, a director of Corvus Pharmaceuticals (CRVS), was granted a derivative award covering 15,000 shares on 2026-06-11. The filing reports the award price as $0.00 (an equity grant/option-type award), so no cash purchase or sale occurred. This is a compensation/award transaction rather than an open-market buy or sell.
Key Details
- Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the standard reporting window).
- Transaction type: Award/Grant of derivative securities (reported code A); 15,000 shares; $0.00 reported price.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Footnote: The award vests 100% on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 annual meeting, subject to continued service as a director.
- No indication in this filing of immediate exercise or sale of underlying shares.
Context
This is a typical director equity award used for compensation and retention. Such grants are routine and do not necessarily signal the insider is buying or selling based on company prospects. Because this is a derivative grant, the economic impact depends on vesting and any future exercise terms (not detailed here).
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-11+15,000→ 15,000 totalExercise: $11.60Exp: 2036-06-11→ Common Stock (15,000 underlying)
Footnotes (1)
- [F1]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.